Evidence map›Paper›PMID 42094724›Full record

ArticleRSC advances2026

Rapid, point-of-care, visual detection of RBD of SARS-CoV-2 spike protein using an acrylamide-free photonic crystal aptasensor.

Meghana Mary Thomas, Parvathy R Chandran, Lekshmi Lekshmanan, A Peer Mohamed, Saju Pillai

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Meghana Mary ThomasMaterials Science and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) Thiruvananthapuram 695 019 India pillai_saju@niist.res.in.
Parvathy R ChandranMaterials Science and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) Thiruvananthapuram 695 019 India pillai_saju@niist.res.in.
Lekshmi LekshmananChemical Sciences and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) Thiruvananthapuram 695 019 India.
A Peer MohamedMaterials Science and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) Thiruvananthapuram 695 019 India pillai_saju@niist.res.in.
Saju PillaiMaterials Science and Technology Division, CSIR-National Institute for Interdisciplinary Science and Technology (NIIST) Thiruvananthapuram 695 019 India pillai_saju@niist.res.in.ORCID https://orcid.org/0000-0001-9855-6899

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As COVID-19 continues to reemerge with new variants, it has become a persistent challenge to public health, causing disruptions in society and the economy. We report a facile photonic crystal-based aptasensor for the rapid visual detection of the receptor-binding domain (RBD) of the severe acute respiratory syndrome (SARS-CoV-2) spike (S) protein. Monodispersed polystyrene@poly(2-hydroxyethyl methacrylate-acrylic acid) [PS@poly(HEMA-AA)] core-shell microspheres were synthesized to fabricate a stimuli-responsive photonic crystal (RPC). The integration of the RBD target-specific aptamer into the poly(HEMA-AA) hydrogel network facilitated the development of a biosensor that enabled RPCs to selectively bind to the SARS-CoV-2 spike protein using coupling chemistry. The interaction between the RBD and a single-stranded DNA aptamer causes the hydrogel to expand, leading to a color change and a shift in the photonic bandgap (PBG). This phenomenon can be used to detect the RBD of the SARS-CoV-2 spike protein. The addition of the RBD of SARS-CoV-2-S-protein to the Apt-RPC aptasensor resulted in a rapid visual color shift from violet to green. The detection range of the developed aptasensor was estimated to be 100-1000 ng with excellent selectivity. Thus, the developed aptasensor offers distinct advantages over conventional detection methods. Our study also facilitates the development of a straightforward point-of-care self-testing kit that does not rely on toxic acrylamide-based chemicals. Furthermore, the sensor eliminates the need for complex sample preparation or signal amplification steps, making it a promising platform for point-of-care diagnosis.

Identifiers

PMID42094724
PMCPMC13142228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.